GCP
RGC icon

GSA Capital Partners’s Regencell Bioscience RGC Stock Holding History

GSA Capital Partners’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,569
Closed -$803K – 2105
2026
Q1 		$803K Buy
+31,569
New +$893K 0.05% 594

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

GSA Capital Partners's RGC Position: Q2 2026 in Review

GSA Capital Partners sold out of Regencell Bioscience (RGC) in Q2 2026, closing a stake of 31,569 shares — an estimated $803K sold.

GSA Capital Partners first reported a position in RGC in Q1 2026 and held it in 1 quarter. The position peaked at $803K in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • GSA Capital Partners reported no remaining Regencell Bioscience position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 31,569 Regencell Bioscience shares in Q2 2026, an estimated $803K.
  • GSA Capital Partners first reported a position in Regencell Bioscience in Q1 2026 and held it in 1 quarter.
  • GSA Capital Partners's Regencell Bioscience position peaked at $803K in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.